Revolution Medicines Reports Third Quarter 2024 Financial …
Nov 6, 2024 · Revolution Medicines is reiterating projected full year 2024 GAAP net loss guidance of between $560 million and $600 million, which includes estimated non-cash stock-based compensation expense of ...
Promising Outlook for Revolution Medicines: Buy Rating Backed …
3 days ago · Moreover, with a robust cash position of $1.55 billion as of the end of 3Q24, Revolution Medicines has a financial runway extending into 2027, providing a solid foundation for ongoing and future ...
Press Releases - Revolution Medicines
Oct 30, 2024 · Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma. October 7, 2024. Revolution Medicines to Deliver Multiple Presentations at the 2024 EORTC-NCI-AACR Symposium and Host Investor Webcast. August 7, 2024.
Revolution Medicines Completes Acquisition of EQRx - Yahoo Finance
REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers,...
Revolution Medicines Doses First Patient in Phase 1/1b Clinical …
Sep 19, 2023 · The Phase 1/1b trial (NCT06040541) is a multicenter, open-label, dose-escalation and dose-expansion study of RMC-9805 in patients with advanced solid tumors harboring the KRAS G12D mutation.
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call …
Nov 7, 2024 · G&A Expenses: $24.0 million for Q3 2024, up from $15.5 million in Q3 2023. Net Loss: $156.3 million for Q3 2024, compared to $108.4 million in Q3 2023. Projected Full Year 2024 GAAP Net Loss ...
Revolution Medicines Reports Q3 2024 Results and Progress
Nov 7, 2024 · Revolution Medicines reported a cash position of $1.55 billion as of September 30, 2024, with increased R&D and G&A expenses contributing to a net loss of $156.3 million for the quarter.
Revolution Medicines, Inc. to Acquire EQRx, Inc. in
Aug 1, 2023 · Revolution Medicines announces today that an update on the clinical antitumor activity of RMC-6236 (RAS MULTI) in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer will be...
Revolution Medicines firms up Phase 3 trial plans with latest …
Jul 15, 2024 · Revolution Medicines said it plans to advance the 300 milligram dose of RMC-6236 into a Phase 3 study comparing it to investigator’s choice of standard chemo among previously treated people with pancreatic cancer.
Revolution Medicines Reports Third Quarter 2024 ... - Markets …
Nov 6, 2024 · Revolution Medicines is reiterating projected full year 2024 GAAP net loss guidance of between $560 million and $600 million, which includes estimated non-cash stock-based compensation expense of ...
- Some results have been removed